# **DABUR INDIA Ltd.**

India Equity Analytics 1-Nov-18 Company Update



Industry Bloomberg BSE CODE Cons. Staples DABUR IN 500096

Volume impacted by shifting of festive season and moderation in rural demand.

RATING	ACCUMULATE
CMP	385
Price Target	442
<b>Potential Upside</b>	15%

Rating Change	1
Estimate Change	1
Target Change	1

### **Key Highlights -**

- □ Dabur's number was below than our expectations, sales grew by 8% to Rs 2125cr( vs expec. Rs 2244 cr) while PAT grew by 4% to Rs 378 cr( vs expec. Rs 413cr).
- □ Domestic Volume growth for the quarter remained 8% impacted by shifting of festive season,moderation in rural growth and increased competitive intensity in Oral space.
- ☐ The company took price hike of 1.5% while promotions increased by 100 bps YoY in Q2FY19. Realization for this quarter was 0.5%.
- □ Decline in Gross margin by 75 bps largely remained inline to our estimates whereas company reported shrinkage in Ebitda margin by 22 bps (vs our expec of improv. of 46 bps) led by higher employee expenses. Ad expenses were lower due to shift of festivals in next quarter.
- □ International business grew by 7% in cc terms impacted by decline in the growth of GCC markets (by 7% YoY) due to consumption pressure and sharp decline in categories. Traction from Namaste was also not so encouraging considering lower base.

#### 2Q FY19 Results-

Sales increased by 8% YoY led by growth in Home & Personal Care (HPC) and Healthcare which grew by 10% and 11% respectively in Q2FY19 while food business growth remained muted due to shifting of the festive season from Q2 to Q3. Oral care which used be one of the growth driver for the company grew by 4% impacted by decline in Babul's sales due to high competitive intensity at economy price points. Higher input prices led to shrinkage in gross margin by 75 bps and higher employee cost dented Ebitda margin by 22 bps. The company has increased its direct reach to target of 1 mn outlets in Mar-18.

#### **View and Valuation**

Dabur has posted numbers below than our expectations; sales grew by 8% while PAT growth remained 4% impacted by lower margins. International business grew by 7% in cc terms impacted by weakness in the MENA region and currency headwinds. Growth was also impacted by shifting of festive season from Q2 to Q3.Going forward, we expect volume to recover led by festive season demand , revival in rural demand (led by higher MSP and government initiatives) and company's efforts on increasing direct reach while mild pressure in margin can be witnessed led by inflation in input prices. Considering weak Q2FY19 numbers and margin headwinds, we have reduced our sales and PAT estimates by 3%/4% and 6%/4% respectively and lower our target price to 442(42xFY20e's eps) from Rs 460 and recommend Accumulate.

## Key Risks to our rating and target

☐ Lower rural growth and sharp increase in the input prices.

KEY FINANCIAL/VALUATIONS	FY16	FY17	FY18	FY19E	FY20E
Net Sales	7869	7701	7748	8614	9821
EBITDA	1518	1509	1617	1766	2179
EBIT	1385	1366	1455	1594	1997
PAT	1251	1277	1354	1468	1853
EPS (Rs)	7	7	8	8	11
EPS growth (%)	17%	2%	6%	8%	26%
ROE (%)	30%	26%	24%	25%	28%
ROCE (%)	28%	24%	22%	24%	27%
BV	24	28	32	33	38
P/B (X)	12	11	11	12	10
P/E (x)	39	43	48	46	37
_					

#### **Stock Info**

52wk Range H/L	491/313
Mkt Capital (Rs Cr)	68160
Free float (%)	32%
Avg. Vol 1M (,000)	3118
No. of Shares	177
Promoters Pledged %	NA

Research Analyst
RAJEEV ANAND

rajeev.anand@narnolia.com +91-22-62701229

The views expressed above accurately reflect the personal views of the authors about the subject companies and its(their) securities. The authors have not and will not receive any compensation for providing a specific recommendation or view. Narnolia Financial Advisors Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

## 2Q FY 19 Results Below than the estimates

Financials	2QFY18	3QFY18	4QFY18	1QFY19	2QFY19	YoY %	QoQ%	FY17	FY18	YoY %
Net Sales	1,959	1,966	2,033	2,081	2,125	8.5%	2.1%	7,701	7,748	0.6%
Other Income	84	66	73	74	81	-3.7%	10.3%	298	305	2.3%
COGS	977	952	1,002	1,049	1,076	10.1%	2.6%	3,843	3,846	0.1%
Gross Margin	50%	52%	51%	50%	49%	-0.7%	-0.2%	50%	50%	0.3%
Employ. Cost	204	205	181	224	234	15.0%	4.6%	790	793	0.4%
Other Expen.	358	406	365	422	364	1.7%	-13.7%	1,560	1,492	-4.4%
EBITDA	420	404	485	386	451	7.4%	16.8%	1,509	1,617	7.2%
EBITDA Mar.	21%	21%	24%	19%	21%	-0.2%	2.7%	20%	21%	1.3%
Depreciation	40	40	43	43	43	7.5%	0.9%	143	162	13.5%
EBIT	380	363	443	343	408	7.3%	18.7%	1,366	1,455	6.5%
Interest	13	13	13	15	16	16.8%	4.6%	54	53	-1.8%
PBT	451	416	503	402	473	5.0%	17.7%	1,610	1,707	6.0%
Exceptional Item	-	-	-	-	-	-	-	-	15	-
Tax	88	83	105	72	96	9.3%	32.9%	330	335	1.5%
PAT	363	333	397	329	378	4.0%	14.7%	1,277	1,354	6.0%
PAT Margin	19%	17%	20%	16%	18%	-0.8%	2.0%	17%	17%	1%

#### Shift of festivals and moderation in rural demand impacted sales

Sales increased by 8% YoY led by growth in Home & Personal Care (HPC) and Healthcare which grew by 10% and 11% respectively in Q2FY19 while food business growth remained muted due to shifting of the festive season from Q2 to Q3. Oral care which used be one of the growth driver for the company grew by 4% impacted by decline in Babul's sales due to high competitive intensity at economy price points. The company is witnessing moderation in rural demand. While rural continues to grow ahead of the urban but not in teens. Higher competition has led sharp decline in Babul's growth, while Red and Miswak franchisee continues to grow. Hair oil category grew by 11.1% with gain in market share of 120 bps. Rise in distribution reach has supported Dabur in clocking 8% volume growth. International business grew by 7% in cc terms continues to face headwinds related to currency.

#### Higher input prices, promotions and incentives impacted margins


Decline in Gross margin by 75 bps largely remained inline to our estimates whereas company reported shrinkage in Ebitda margin by 22 bps (vs our expec of improv. of 46 bps) led by higher employee expenses. Ad expenses were down due to shift of festivals in next quarter. Higher input prices led to shrinkage in gross margin by 75 bps and higher employee cost dented Ebitda margin by 22 bps. Higher promotions(for domestic), incentives(MENA) given to retailers and Cost related to expansion of direct reach have impacted the Ebitda margin.

#### Concall Highlights

- ☐ Rural growth has moderated but remains stable and grew ahead of urban demand by 1.5% in this quarter. ☐ Modern trade continues to grow strongly at the rate above 25%. General trade growth remained one third of modern trade. ☐ As per the Management Patanjali still remains its competitor in oral care while the company has managed to get back its share in Honey and Chayanprash. Competitive intensity from Patanjali has slightly subsided in Honey. ☐ First priority of the company is to maintain and increase market share with volume growth. Little dent in margin is tolerable for the company.
- ☐ The Management expects double digit volume growth for FY19.
- ☐ The Company under took a price hike to the extent of 1.5% in 2QFY19 while increased promotion by 100 bps in comparison to previous quarter. It has further taken price hike in the range of 1-1.5%, hence total pricing growth remained in the range of 2-2.5%.
- ☐ Babul has grown much lower than previous year due to high competitive intensity in lower unit segment. However company is confident of clocking growth above the category growth in Oral care led by Dabur red and Miswak franchisee. The company is also taking corrective steps to bring back Babul growth.
- ☐ Underlying demand growth will dictate new launches in FY19.
- ☐ The Branded OTC business is showing strong traction. The Management expects strong growth from Health care going forwards.


#### Exhibit: Domestic FMCG Volume Growth(%)

Domestic Volume growth for the quarter remained 8% impacted by shifting of festive season.




## **Exhibit: Gross and EBITDA Margin**

Higher input prices led to shrinkage in gross margin by 75 bps and higher empl. cost dented Ebitda margin by 22 bps.




#### **Exhibit: PAT and PAT Growth**

PAT grew by 4% to Rs 378 cr( vs expec. Rs 413cr)due to shrinkage in operating margin.




#### **Exhibit: Sales and Sales Growth**

Dabur's number was below than our expectation, sales grew by 8% to Rs 2125cr( vs expec. Rs 2244 cr)




## Exhibit: Employee and Ad & P expense

Ad expense were lower this quarter due to shifting of festive season from Q2 to Q3.



#### **Exhibit: Return on Equity**

We expect ROE to improve for Dabur going forward by 123 and 256 bps in FY19e and FY20e respectively.



## **Financial Details**

## **Balance Sheet**

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
Share Capital	174	174	176	176	176	176	176	176
Reserves	1,921	2,482	3,178	3,995	4,671	5,530	5,704	6,556
Networth	2,095	2,656	3,354	4,171	4,847	5,707	5,880	6,732
Debt	1,151	708	734	792	912	829	680	605
Other Non Current Liab	85	86	105	144	165	170	185	200
Total Capital Employed	3,247	3,364	4,088	4,963	5,759	6,535	6,560	7,337
Net Fixed Assets (incl CWIP)	1,674	1,789	1,927	1,773	2,000	2,070	2,175	2,260
Non Current Investments	163	493	1,407	1,881	2,499	3,092	3,092	3,692
Other Non Current Assets	1,856	1,831	1,968	1,836	2,115	2,170	2,255	2,340
Non Current Assets	2,019	2,324	3,376	3,717	4,614	5,262	5,347	6,032
Inventory	844	973	973	1,097	1,107	1,256	1,397	1,592
Debtors	484	675	711	809	650	706	785	895
Cash & Bank	362	519	276	220	305	306	288	338
Other Current Assets	59	42	86	309	280	391	435	496
Current Assets	2,689	2,988	2,731	3,216	3,116	3,440	3,617	4,035
Creditors	717	1,097	1,096	1,330	1,303	1,410	1,568	1,788
Provisions	215	270	256	92	92	107	119	136
Other Current Liabilities	433	479	544	232	175	173	192	219
Curr Liabilities	1,365	1,846	1,896	1,805	1,782	1,970	2,190	2,497
Net Current Assets	1,324	1,142	835	1,411	1,334	1,470	1,427	1,538
Total Assets	4,709	5,312	6,106	6,932	7,731	8,702	8,964	10,067

## **Income Statement**

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
Revenue from Operation	6,169	7,075	7,827	7,869	7,701	7,748	8,614	9,821
Change (%)		15%	11%	1%	-2%	1%	11%	14%
EBITDA	988	1,160	1,316	1,518	1,509	1,617	1,766	2,179
Change (%)		17%	14%	15%	-1%	7%	9%	23%
Margin (%)	16%	16%	17%	19%	20%	21%	20%	22%
Depr & Amor.	85	97	115	133	143	162	172	182
EBIT	903	1,062	1,201	1,385	1,366	1,455	1,594	1,997
Int. & other fin. Cost	59	54	40	48	54	53	62	46
Other Income	109	128	158	217	298	305	307	372
EBT	953	1,136	1,319	1,554	1,610	1,707	1,839	2,322
Exp Item	5	1	-	-	-	15	-	-
Tax	183	219	251	300	330	335	368	466
Minority Int & P/L share of Ass.	2	3	3	3	3	3	3	3
Reported PAT	763	914	1,066	1,251	1,277	1,354	1,468	1,853
Adjusted PAT	760	913	1,066	1,251	1,277	1,342	1,468	1,853
Change (%)		20%	17%	17%	2%	6%	8%	26%
Margin(%)	12%	13%	14%	16%	17%	17%	17%	19%

## **Financial Details**

# **Key Ratios**

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
ROE	36%	34%	32%	30%	26%	24%	25%	28%
ROCE	28%	32%	29%	28%	24%	22%	24%	27%
Asset Turnover	1	1	1	1	1	1	1	1
Debtor Days	29	35	33	38	31	33	33	33
Inv Days	50	50	45	51	52	59	59	59
Payable Days	42	57	51	62	62	66	66	66
Int Coverage	15	20	30	29	25	27	26	43
P/E	31	34	32	39	43	48	46	37
Price / Book Value	11	12	10	12	11	11	12	10
EV/EBITDA	24	27	26	32	36	41	38	31
FCF per Share	4	5	5	6	4	5	8	10
Div Yield	1%	1%	1%	0%	1%	1%	2%	1%

## **Cash Flow Statement**

Y/E March	FY13	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E
PBT	948	1,136	1,319	1,554	1,610	1,693	1,836	2,319
(inc)/Dec in Working Capital	44	82	(118)	(75)	87	(258)	60	(45)
Non Cash Op Exp	84	126	153	132	47	180	172	182
Int Paid (+)	40	33	40	26	31	42	62	46
Tax Paid	(169)	(186)	(230)	(281)	(322)	(325)	(368)	(466)
others	(77)	(92)	(117)	(169)	(216)	(242)	-	-
CF from Op. Activities	870	1,098	1,047	1,187	1,237	1,089	1,762	2,037
(inc)/Dec in FA & CWIP	(224)	(213)	(251)	(189)	(486)	(200)	(278)	(267)
Free Cashflow	646	885	796	998	751	889	1,484	1,769
(Pur)/Sale of Inv	(454)	10	(721)	(688)	(511)	(584)	-	(600)
others	54	95	96	147	180	244	3	3
CF from Inv. Activities	(624)	(107)	(876)	(730)	(817)	(540)	(275)	(864)
inc/(dec) in NW	0	0	46	17	15	-	-	-
inc/(dec) in Debt	83	(443)	25	71	168	(55)	(149)	(75)
Int. Paid	(34)	(34)	(26)	(40)	(45)	(43)	(62)	(46)
Div Paid (inc tax)	(283)	(326)	(462)	(423)	(477)	(477)	(1,295)	(1,000)
others								
CF from Fin. Activities	(234)	(804)	(417)	(374)	(339)	(574)	(1,505)	(1,122)
Inc(Dec) in Cash	12	187	(246)	82	81	(26)	(18)	50
Add: Opening Balance	112	123	313	(47)	35	116	306	288
Closing Balance	125	313	68	35	116	89	288	338

Disclosures: Narnolia Financial Advisors Ltd.\* (NFAL) (FormerlyMicrosec Capital Ltd.) is a SEBI Registered Research Analyst having registration no. INH300002407 valid till 01.12.2020. NFALis engaged in the business of providing Stock Broking, Depository Participant, Merchant Banking, Portfolio Management & distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com

No penalties have been levied on NFAL by any Regulatory/Statutory authority. NFAL, it's associates, Research Analyst or their relative may have financial interest in the subject company. NFAL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report, NFAL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of NFAL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month period. NFAL and/or its associates may have received compensation from the subject company in the past 12 months. In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, NFAL or any of its associates may have: a) managed or co-managed public offering of securities from subject company of this research report, b) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d) Subject Company may have been a client of NFAL or its associates during 12 months preceding the date of distribution of the research report. NFAL and it's associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. NFAL and / or its affiliates may do and seek to do business including Investment Banking with companies covered in the research reports. As a result, the recipients of this report should be aware that NFAL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific Merchant Banking. Investment Banking or Brokerage service transactions, Research Analyst's views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of NFAL or its associates maintains arm's length distance with Research Team as all the activities are segregated from NFAL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views

Terms & Conditions: This report has been prepared by NFAL and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document fincluding the merits and risks involved), and should consult his/her/its

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### **Disclosure of Interest Statement-**

Analyst's ownership of the stocks mentioned in the Report	NIL
---	-----

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com.

\*The name of the Company has been changed from "Microsec Capital Limited" to "Narnolia Financial Advisors Limited" pursuant to change of control. The change in name has been duly effected in the records of the Registrar of Companies (ROC). The application for fresh registration in the new name of "Narnolia Financial Advisors Limited" pursuant to change of control is under process with SEBI.

Correspondence Office Address: Arch Waterfront, 5<sup>th</sup> Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com. Registered Office Address: Marble Arch, Office 201, 2<sup>nd</sup> Floor, 236B, AJC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com

Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.

Registration details of Company: Narnolia Financial Advisors Ltd. (NFAL): SEBI Stock Broker Registration: INZ000166737 (NSE/BSE/MSEI); NSDL/CDSL: IN-DP-380-2018; Research Analyst: INH300002407, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFIRegistered Mutual Fund distributor: ARN 3087

Registration Details of Group entities: G. Raj & Company Consultants Ltd (G RAJ)-BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 || Narnolia Commerze Limited-MCX/NCDEX Commodities Broker: INZ000051636 || Narnolia Velox Advisory Ltd. SEBI Registered PMS: INP000005109 || Eastwind Capital Advisors Pvt Ltd. (EASTWIND)-SEBI Registered Investment Adviser: INA300005439 || Narnolia Insurance Brokers Limited-IRDA Licensed Direct Insurance Broker (Life & Non-Life) License No.134 || Narnolia Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 || Narnolia Capital Advisors Pvt. Ltd. - RBI Registered NBFC:8.05.02568.

#### Disclaimer:

This report has been prepared by Narnolia Financial Advisors Ltd. (NFAL)and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific ircumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should cons

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.